BioSpace News Archive

The primary analysis of investigational, once-nightly FT218 at 9 g demonstrated highly statistically significant (p<0.001), and clinically meaningful improvement across all three co-primary endpoints compared to placebo

Partnerships and programs address the social determinants of health across Mississippi

Preliminary data in moderate-to-severe COVID-19 patients treated with opaganib show measurable clinical improvement in all six patients analyzed, including decreased requirement for supplemental oxygenation, higher lymphocyte counts and decreased CRP

TH1902 and TH1904 more effective and safer in vivo compared to current standard ovarian cancer treatments New data presented during the AACR Virtual Annual Meeting

Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its first quarter 2020 financial results after market close on Tuesday, May 5 , 2020. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30pm Eastern Time ( 1:30pm Pacific Time ) to discuss th

Phagelux AgriHealth, Inc., a global agriculture biotechnology company focused on the development and commercialization of novel phage products and solutions, recently made multiple announcements about new collaborations. Ryan Benson , Director of US Sales and Marketing for OmniLytics, Inc., a wholly

Epizyme, Inc. announced that management will host a conference call and webcast to discuss its first quarter 2020 financial results and other business highlights on Monday, May 4, 2020 at 9:00 a.m. ET.

Merck, known as MSD outside the United States and Canada, and the Institute for Systems Biology, announced a new research collaboration to investigate and define the molecular mechanisms of SARS-CoV-2 infection and COVID-19 and identify targets for medicines and vaccines.

Orchard Therapeutics, a global gene therapy leader, announced that the first patient has been dosed in an open-label, proof-of-concept investigational study of OTL-201, an ex vivo autologous hematopoietic stem cell gene therapy for the treatment of mucopolysaccharidosis type IIIA.

Arcturus Therapeutics Holdings Inc., a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, announced positive immunogenicity data from its preclinical study for the Company’s COVID-19 Vaccine.